This page shows the latest Relvar news and features for those working in and with pharma, biotech and healthcare.
The combination is currently being considered by European regulatory authorities and if approved GSK plans to sell it as Relvar.
Aside from Breo ( known as Relvar outside the US), Elan will get royalties on sales of COPD combination therapy Anoro ( umeclidinium bromide and vilanterol), vilanterol as a monotherapy and GSK961081, a
Meanwhile, GSK and Theravance's respiratory collaboration also led to the approval of Relvar/Breo ( fluticasone/vilanterol), a direct successor to Advair. ... Both Anoro and Relvar are critical new drugs for GSK as it prepares for competition to Advair,
Important step towards eventually replacing Seretide/Advair sales
Elsewhere, GSK followed up approval in Japan for its respiratory medicine Relvar Ellipta with a CHMP recommendation for use in asthma and COPD, while Plethora Solution's Lidocaine/ Prilocaine Plethora was backed
The Japanese Ministry of Health, Labour and Welfare ( MHLW) cleared GlaxoSmithKline's ( GSK) Relvar Ellipta ( vilanterol and fluticasone), as well as Kyorin Pharmaceutical's Flutiform ( formoterol and fluticasone) for the treatment of bronchial
More from news
Approximately 2 fully matching, plus 14 partially matching documents found.